research use only
Cat.No.S4685
| Related Targets | Integrase Bacterial Antibiotics Anti-infection Fungal Antiviral COVID-19 Parasite HIV HCV Protease |
|---|---|
| Other Reverse Transcriptase Inhibitors | Dapivirine (TMC120) Fangchinoline 3'-Fluoro-3'-deoxythymidine (Alovudine) Salicylanilide Bifendate Ulonivirine Islatravir Lersivirine (UK-453061) 4-Chloro-2-(trifluoroacetyl)aniline hydrochloride |
|
In vitro |
DMSO
: 63 mg/mL
(199.57 mM)
Ethanol : 63 mg/mL Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 315.67 | Formula | C14H9ClF3NO2 |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 154598-52-4 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | DMP-266 | SMILES | C1CC1C#CC2(C3=C(C=CC(=C3)Cl)NC(=O)O2)C(F)(F)F | ||
Read more about storage stability stock solution CAS number SMILES
| Targets/IC50/Ki |
Reverse transcriptase
|
|---|---|
| In vitro |
Efavirenz has direct inhibitory effect on the mitochondrial respiratory function of cultured glioblastoma and differentiated neuroblastoma cell lines. ER stress markers, including CHOP and GRP78 expression (both protein and mRNA), phosphorylation of eIF2a, and presence of the spliced form of XBP1 are upregulated. This compound also enhances cytosolic Ca2+ content and induced morphological changes in the ER suggestive of ER stress. This response is greatly attenuated in cells with altered mitochondrial function (Rho). The effects of this chemical on the ER, and particularly in regard to the mitochondrial involvement, differs from those elicited by a standard pharmacological ER stressor.
|
| In vivo |
Efavirenz leads to arterial stiffening but, for the dose and duration tested, did not lead to elevated plaque progression in ApoE(-/-) mice.
|
References |
|
(data from https://clinicaltrials.gov, updated on 2026-09-03)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT07482085 | RECRUITING | Creutzfeldt-Jakob Disease |
Xuanwu Hospital, Beijing |
2026-04-14 | PHASE3 |
| NCT07631897 | NOT_YET_RECRUITING | HIV; Art Therapy; TB - Tuberculosis |
Shanghai Public Health Clinical Center |
2026-06 | PHASE4 |
| NCT06823596 | RECRUITING | Hiv |
University of Toronto |
2025-01-14 | |
| NCT05789173 | RECRUITING | Drug-Drug Interaction |
Indiana University |
2023-10-06 | EARLY_PHASE1 |
| NCT07341672 | NOT_YET_RECRUITING | Healthy Adult Subject |
Sunshine Lake Pharma Co., Ltd. |
2026-12-31 | PHASE1 |
| NCT05076682 | RECRUITING | Triple-negative Breast Cancer |
Fudan University |
2022-06-30 | PHASE2 |
Read more about Clinical Trials
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.